Univ. Bordeaux, 33000, Bordeaux, France; INSERM UMR1029, 33400, Pessac, France.
Univ. Bordeaux, 33000, Bordeaux, France; Institut Bergonié, 33076, Bordeaux, France.
Cancer Lett. 2020 Mar 31;473:50-61. doi: 10.1016/j.canlet.2019.12.027. Epub 2019 Dec 30.
Many cancers occur from locations of inflammation due to chronic irritation and/or infection. Tumor microenvironment contains various different inflammatory cells and mediators that orchestrate diverse neoplastic processes, including proliferation, survival, adhesion and migration. In parallel, tumor cells have adapted some of the signaling molecules used by inflammatory cells, such as selectins and chemokines as well as their receptors for invasion, extravasation and subsequently metastasis. Expression and/or activation of the majority of these molecules is mediated by the proprotein convertases (PCs); proteases expressed by both tumor cells and inflammatory cells. This review analyzes the potential role of these enzymatic system in inflammation-associated cancer impacting on the malignant and metastatic potential of cancer cells, describing the possible use of PCs as a new anti-inflammatory therapeutic approach to tumor progression and metastasis.
许多癌症是由慢性刺激和/或感染引起的炎症部位发生的。肿瘤微环境中含有各种不同的炎症细胞和介质，它们协调多种肿瘤发生过程，包括增殖、存活、黏附和迁移。同时，肿瘤细胞已经适应了炎症细胞使用的一些信号分子，如选择素和趋化因子及其用于侵袭、渗出和随后转移的受体。这些分子的表达和/或激活大多数是由前蛋白转化酶（PCs）介导的；PCs 是由肿瘤细胞和炎症细胞表达的蛋白酶。这篇综述分析了这些酶系统在炎症相关癌症中的潜在作用，这些癌症影响癌细胞的恶性和转移潜能，描述了将 PCs 用作肿瘤进展和转移的新的抗炎治疗方法的可能性。
